CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Agalsidase alfa

Last Updated: February 19, 2004
Result type: Reports
Project Number: S0006
Product Line: Reimbursement Review

Generic Name: Agalsidase alfa

Brand Name: Replagal

Manufacturer: Transkaryotic Therapies Inc.

Indications: Fabry Disease

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: November 24, 2004

Recommendation Type: Do not list